Key Quantitative Figures

The Board of Directors, at their meeting held on May 22, 2026, recommended a final dividend of ₹5 per equity share of face value Re. 1 each for the financial year ended March 31, 2026.

Dates of Action and Deadlines

  • Board Meeting Date: May 22, 2026
  • Record Date for Dividend Eligibility: Friday, July 24, 2026
  • Deadline for Document Submission: August 14, 2026 (for all TDS-related forms and declarations)
  • Disclosure Date to Exchanges: August 1, 2026

Parties Involved

  • Issuer: Jubilant Pharmova Limited (CIN: L24116UP1978PLC004624)
  • Registrar & Share Transfer Agent (RTA): Alankit Assignments Limited
  • Regulatory Reference: SEBI Listing Regulations, Income-tax Act, 2025
  • Company Contact: investors@jubl.com
  • RTA Contact: rta@alankit.com

TDS Procedures and Rates

Resident Shareholders

  • No TDS if total dividend during FY 2026-27 does not exceed ₹10,000 for an individual.
  • 10% TDS if valid PAN is updated in the Company's register. No document required.
  • 20% TDS if no PAN/valid PAN not updated/PAN not linked with AADHAR (for individuals exceeding ₹10,000 dividend; for non-individuals, regardless of amount).
  • Nil TDS is possible upon submission of specific documents (e.g., Form 121, exemption proofs for LIC/GIC, SEBI cert for Category I/II AIF, proof for NPS, recognized PF funds, etc.) by August 14, 2026.

Non-Resident Shareholders

  • Default Rate: 35% (plus applicable surcharge and cess) if no documents are provided.
  • Beneficial DTAA Rates may apply upon submission of a valid Tax Residency Certificate (TRC), PAN/declaration as per Rule 217, e-filed Form 41, and a self-declaration for non-existence of a Permanent Establishment (PE) in India.
  • Nil TDS for Indian Branch of a Foreign Bank upon submission of a self-declaration and lower tax certificate.
  • The application of beneficial treaty rates is subject to the Company's review and verification.

Financial and Operational Impact

The financial impact is the distribution of the proposed dividend, subject to shareholder approval. The TDS deducted will be remitted to the government, affecting the net cash receipt of shareholders.

Capital Structure Impact

No impact on the capital structure or share capital is mentioned. The disclosure pertains only to the distribution of profits.

Additional Important Notes

  • The Company will issue a soft copy of the TDS certificate (Form 168) via email post-filing of the TDS return.
  • Documents can be uploaded to rta@alankit.com or mailed to investors@jubl.com.
  • NSDL provides a facility for certain institutional members to submit documents through their custodian.
  • The Company reserves the right to verify PAN status and other particulars and apply the appropriate tax rate independently.
  • Shareholders with multiple accounts under a single PAN will be taxed at the highest applicable rate across all holdings.
  • Shareholders are responsible for any tax demands arising from misrepresentation and must indemnify the Company.
  • This communication is not exhaustive, and shareholders should consult their tax advisors.

Disclaimer

The communication explicitly states it is not a complete analysis of all potential tax consequences and advises shareholders to consult their tax advisors.